0001209191-24-001973.txt : 20240119 0001209191-24-001973.hdr.sgml : 20240119 20240119203502 ACCESSION NUMBER: 0001209191-24-001973 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240119 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rouan Sarah Kathryn CENTRAL INDEX KEY: 0001761366 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 24546892 MAIL ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-19 0 0001607678 Viking Therapeutics, Inc. VKTX 0001761366 Rouan Sarah Kathryn C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 1 0 0 0 1 Common Stock, par value $0.00001 per share 2024-01-19 4 M 0 30000 8.32 A 30000 D Common Stock, par value $0.00001 per share 2024-01-19 4 S 0 30000 23.05 D 0 D Stock Option (Right to Buy) 8.32 2024-01-19 4 M 0 30000 0.00 D 2020-07-01 2029-07-01 Common Stock 30000 25000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023. /s/ Michael Morneau as Attorney-in-Fact 2024-01-19